Introduced in Senate on Jun 21, 2023
Introduced in House
Sponsorship: Democrat, Tammy Baldwin, Wisconsin, Republican, Thom Tillis, North Carolina
House Bill 3832
Disease X Act of 2023
S. 2093
To establish a program at BARDA for developing medical countermeasures for viral threats with pandemic potential.
IN THE SENATE OF THE UNITED STATES
June 21, 2023
Ms. Baldwin (for herself and Mr. Tillis) introduced the following bill; which was read twice and referred to the Committee on Health, Education, Labor, and Pensions
A Bill
To establish a program at BARDA for developing medical countermeasures for viral threats with pandemic potential.
Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,
SECTION 1. Short title.
This Act may be cited as the “Disease X Act of 2023”.
SEC. 2. Medical countermeasures for viral threats with pandemic potential.
(a) In General.—Section 319L(c)(4) of the Public Health Service Act (42 U.S.C. 247d–7e(c)(4)) is amended—
(1) in subparagraph (D)—
(A) in clause (ii), by striking “; and” and inserting a semicolon;
(B) by redesignating clause (iii) as clause (v); and
(C) by inserting after clause (ii) the following:
“(iii) the identification and development of platform manufacturing technologies needed for advanced development and manufacturing of medical countermeasures for viral families which have significant potential to cause a pandemic;
“(iv) advanced research and development of flexible medical countermeasures against priority respiratory virus families and other respiratory viral pathogens with a significant potential to cause a pandemic, with both pathogen-specific and pathogen-agnostic approaches; and”; and
(2) in subparagraph (F)—
(A) in clause (ii), by striking “; and” at the end and inserting a semicolon;
(B) in clause (iii), by striking the period and inserting “; and”; and
(C) by adding at the end the following:
“(iv) priority virus families and other viral pathogens with a significant potential to cause a pandemic.”.
(b) Funding.—Section 319L(d)(2) of the Public Health Service Act (42 U.S.C. 247d–7e(d)(2)) is amended—
(1) by striking “To carry out” and inserting the following:
“(i) IN GENERAL.—To carry out”; and
(2) by adding at the end the following:
“(ii) ADDITIONAL FUNDING.—
“(I) IN GENERAL.—In addition to the amounts appropriated under clause (i), there is authorized to be appropriated to the Fund $40,000,000 for each of fiscal years 2024 through 2028, which amounts shall be used solely for purposes of carrying out clauses (iii) and (iv) of subsection (c)(4)(D), such amounts to remain available until expended.
“(II) RESTRICTION ON USE OF FUNDS.—Any product developed using funding appropriated pursuant to subclause (I) shall be substantially manufactured in the United States. The Secretary may waive the requirements of this subclause with respect to individual entities if the Secretary determines that requiring domestic research and development operations would be inconsistent with the public interest.”.
https://www.billsponsor.com/bills/483231/senate-bill-2093-congress-118
https://www.billsponsor.com/bills/483231/senate-bill-2093-congress-118/text/is